Antifungal agents in children.

Journal Article (Journal Article;Review)

Fungal pathogens are an increasingly recognized complication of organ transplantation and the ever more potent chemotherapeutic regimens for childhood malignancies. This article provides a brief overview of the current state of systemic antifungal therapy. Currently licensed drugs, including amphotericin B and its lipid derivates; 5-fluorocytosine; the azoles, including fluconazole, itraconazole, and voriconazole; and a representative of the new class of echinocandin agents, caspofungin, are discussed. Newer second-generation azoles (posaconazole and ravuconazole) and echinocandins (micafungin and anidulafungin) that are likely to be licensed in the United States in the next few years also are addressed.

Full Text

Duke Authors

Cited Authors

  • Steinbach, WJ

Published Date

  • June 2005

Published In

Volume / Issue

  • 52 / 3

Start / End Page

  • 895 - viii

PubMed ID

  • 15925667

International Standard Serial Number (ISSN)

  • 0031-3955

Digital Object Identifier (DOI)

  • 10.1016/j.pcl.2005.02.009


  • eng

Conference Location

  • United States